NeuroNation, accelerating cognitive health through digital therapeutics
A leading European player in digital therapeutics dedicated to cognitive health, NeuroNation has established itself over the past decade as an innovative solution for the prevention and management of cognitive decline. Founded in 2011, the company initially developed a cognitive training platform for the general public, before evolving into a major digital therapeutics player at the intersection of mental health, neurology, and prevention.
IMPACT Partners is proud to have supported NeuroNation since 2020 during a key phase of strategic transformation, alongside its founders Jakob Futorjanski and Rojahn Ahmadi, notably by helping finance clinical studies and secure CE marking and DiGA certification in Germany, enabling reimbursement through the German healthcare system and positioning NeuroNation MED as one of the most widely prescribed applications in its field in the country.
Over five years, NeuroNation has experienced strong growth, reaching approximately €10 million in revenue and relying on a solid scientific foundation with 16 clinical studies conducted on more than 8,500 participants. Today, the solution has supported more than 50,000 patients in managing cognitive decline and more than 30 million users worldwide.
In 2026, IMPACT Partners is selling its stake to the pharmaceutical group Schwabe, a leading family-owned player in neurocognitive health. This transaction delivers an exit multiple of more than 5x the initial investment and opens a new development phase for NeuroNation, with the ambition of accelerating its international expansion and broadening its therapeutic indications.
This partnership illustrates IMPACT Partners’ conviction: supporting entrepreneurs who sustainably transform access to care through innovative, scientifically validated solutions capable of scaling.